JP2025517656A5 - - Google Patents
Info
- Publication number
- JP2025517656A5 JP2025517656A5 JP2024566198A JP2024566198A JP2025517656A5 JP 2025517656 A5 JP2025517656 A5 JP 2025517656A5 JP 2024566198 A JP2024566198 A JP 2024566198A JP 2024566198 A JP2024566198 A JP 2024566198A JP 2025517656 A5 JP2025517656 A5 JP 2025517656A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug
- linker
- pharmaceutical composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340745P | 2022-05-11 | 2022-05-11 | |
| US63/340,745 | 2022-05-11 | ||
| PCT/IB2023/054841 WO2023218378A1 (en) | 2022-05-11 | 2023-05-10 | Combination of an antibody specific for a tumor antigen and a cd47 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517656A JP2025517656A (ja) | 2025-06-10 |
| JP2025517656A5 true JP2025517656A5 (enExample) | 2026-05-18 |
Family
ID=86851891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566198A Pending JP2025517656A (ja) | 2022-05-11 | 2023-05-10 | 腫瘍抗原に特異的である抗体と、ｃｄ４７阻害剤との組合せ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250296966A1 (enExample) |
| EP (1) | EP4522658A1 (enExample) |
| JP (1) | JP2025517656A (enExample) |
| CN (1) | CN119403829A (enExample) |
| TW (1) | TW202400650A (enExample) |
| WO (1) | WO2023218378A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118767148B (zh) * | 2024-06-24 | 2025-09-05 | 武汉科技大学 | 一种提高红细胞载体实体肿瘤富集能力的方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| NZ579644A (en) | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| JP6282232B2 (ja) | 2012-02-10 | 2018-02-21 | ユニバーシティー オブ メリーランド，ボルティモア | 抗体及びそのＦｃフラグメントの酵素化学的糖鎖改変 |
| JP6081125B2 (ja) | 2012-10-09 | 2017-02-15 | 株式会社日立製作所 | 太陽光発電装置および電力管理システム、並びに、そのための電力負荷と計測装置 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| ME03550B (me) | 2012-12-17 | 2020-07-20 | Trillium Therapeutics Inc | Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| US11185594B2 (en) | 2014-04-10 | 2021-11-30 | Daiichi Sankyo Company, Limited | (Anti-HER2 antibody)-drug conjugate |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| ES2916217T3 (es) | 2017-01-05 | 2022-06-29 | Kahr Medical Ltd | Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma |
| SG11201906554RA (en) | 2017-01-17 | 2019-08-27 | Daiichi Sankyo Co Ltd | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| WO2018236904A1 (en) | 2017-06-19 | 2018-12-27 | Surface Oncology, Inc. | COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| WO2020198370A2 (en) | 2019-03-25 | 2020-10-01 | Arch Oncology, Inc. | Therapeutic cd47 antibodies |
| CA3141130A1 (en) * | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
-
2023
- 2023-05-10 JP JP2024566198A patent/JP2025517656A/ja active Pending
- 2023-05-10 TW TW112117337A patent/TW202400650A/zh unknown
- 2023-05-10 US US18/863,639 patent/US20250296966A1/en active Pending
- 2023-05-10 EP EP23731743.3A patent/EP4522658A1/en active Pending
- 2023-05-10 WO PCT/IB2023/054841 patent/WO2023218378A1/en not_active Ceased
- 2023-05-10 CN CN202380039750.7A patent/CN119403829A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7553504B2 (ja) | 操作された抗体化合物およびこれらの抱合体 | |
| TWI843705B (zh) | 結晶及其改良製造方法、以及抗體-藥物結合物之改良製造方法 | |
| JP6585600B2 (ja) | Ｃ末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法 | |
| TWI822740B (zh) | 抗her2雙互補位抗體-藥物結合物及使用方法 | |
| CN116271079B (zh) | 一种抗dll3抗体及其制备方法、其药物偶联物和应用 | |
| JPWO2022102634A5 (enExample) | ||
| JP2020531469A (ja) | 三環式基を有するトル様受容体７（ｔｌｒ７）アゴニスト、そのコンジュゲート、ならびにそれらの方法および使用 | |
| WO2015165413A1 (zh) | 一种新型的稳定型抗体药物耦联物及其制备方法和用途 | |
| JP2015526435A (ja) | 抗体成分と血液脳関門を通過するポリペプチドと細胞毒とを含むコンジュゲート | |
| JP2020521478A5 (enExample) | ||
| JP2020532523A (ja) | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 | |
| TWI845724B (zh) | 用於偶聯的多肽複合物及其應用 | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| AU2015340370A9 (en) | Materials and methods relating to linkers for use in protein drug conjugates | |
| JP2025129192A (ja) | 胆道癌の治療のための、ｈｅｒ２を標的とする二重特異性抗原結合構築物の使用方法 | |
| JP2020532543A (ja) | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 | |
| Kim et al. | Bispecific anti-mPDGFRβ x cotinine scFv-Cκ-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFRβ expressing cells | |
| WO2025119257A1 (zh) | 间皮素靶向结合蛋白、其编码核酸以及用途 | |
| JPWO2023219072A5 (enExample) | ||
| WO2016059057A1 (en) | Vegfr-2 binding polypeptides | |
| WO2025021073A1 (zh) | 抗Nectin4抗体药物偶联物和抗PD-1抗体的药物组合以及其用途 | |
| WO2026082091A1 (zh) | 一种包含特异性结合egfr和muc1的抗体药物偶联物的药物组合物 | |
| US8597655B2 (en) | Recombinant fusion protein and polynucleotide construct for immunotoxin production | |
| 김수현 | Bispecific anti-mPDGFRβ/cotinine fusion protein can form antibody-drug conjugate-like complexes with cotinine-duocarmycin and exert cytotoxicity against mPDGFRβ expressing cells | |
| CN119462950A (zh) | 结合trop2和/或prlr的双特异性抗原结合分子、其缀合物和用途 |